A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx
A clinical study to compare the efficacy and safety of AK105 plus anlotinib and Capecitabine/Oxaliplatin (CapeOx) , anlotinib plus CapeOx, bevacizumab plus CapeOx. A total of 120 cases will be enrolled to the group.
Unresectable Metastatic Colorectal Cancer
DRUG: AK105 injection|DRUG: Anlotinib hydrochloride capsule|DRUG: CapeOX|DRUG: Bevacizumab
Disease progression-free survival(PFS), According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, the time between the beginning of randomization and the first occurrence of objective disease progression or recurrence or death from various causes (whichever occurs first)., up to 8-10 months|Overall survival (OS), Refers to the time between random grouping and death caused by various causes., up to 20-30 months|Objective remission rates(ORR), Percentage of subjects with complete remission (CR) or partial remission (PR) as determined by RECIST 1.1., up to 30 months|Disease Control Rate (DCR), Percentage of subjects with CR, PR, or disease stabilization (SD) at 6 weeks or more as determined by RECIST 1.1., up to 30 months
Duration of disease remission (DOR), For subjects whose best remission is CR or PR, it is defined as from the date when tumor remission is first recorded to the date when disease progression is first recorded or the date of death from any cause (whichever occurs first)., up to 20-30 months
A clinical study to compare the efficacy and safety of AK105 plus anlotinib and Capecitabine/Oxaliplatin (CapeOx) , anlotinib plus CapeOx, bevacizumab plus CapeOx. A total of 120 cases will be enrolled to the group.